Search Results

MC# 20-16
An Open-Label, Multicenter, Phase IB/II Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects with Advanced Solid Tumors

MC# 20-17
A Phase I, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of T3011 in Advanced Cutaneous or Subcutaneous Malignancies

MC# 20-23
An Open-Label, Multicenter Phase I/II Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors

MC# 20-25
A Phase I Study of SRF617 in Patients With Advanced Solid Tumors (SRF61-101)

MC# 20-26
Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

MC# 20-27
A Phase Ib Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MC# 20-30
Phase I study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies

MC# 20-40
A Phase I Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

MC# 21-02
An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors

MC# 21-07
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination with a MEK Inhibitor in Patients with Advanced or Metastatic Solid Tumors

MC# 21-08
Phase I First-in-Human (FIH) Study of Leukocyte Immunoglobulin- Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

MC# 21-11
A Multicenter, Phase 1, Open-Label Study of SQ3370 in Patients with Advanced Solid Tumors

MC# 21-12
An Exploratory Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy

MC# 19-05
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 20-09
A Phase Ib, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 20-33
A Phase Ib/II, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR- 255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors

MC# 21-17
A Phase I/II Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

MC# 19-31
A Phase I, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab

MC# 19-33
A Phase I, Open-label Single-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies

MC# 20-19
A Phase I, Open-Label Multi-Dose Two-Part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438), And The Effects Of A Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat in Subjects with Advanced Malignancies

MC# 21-06
Phase I, First-in-Human, Open-Label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients with Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

MC# 19-12
Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

MC# 19-21
A Phase I/IIa Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy

MC# 20-01
A Phase I First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

MC# 20-11
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors